11 April 2022 - Deborah Wilkes
Premium
GlaxoSmithKline (GSK) Consumer Healthcare is considering a licensing deal for Cann Group’s cannabidiol (CBD) capsule in Australia and other markets worldwide.
New to OTCToolbox?
This is available as part of an Annual Subscription to the OTCToolbox website.